West Pharmaceutical Services (WST) Profit After Tax (2009 - 2026)

West Pharmaceutical Services (WST) has reported Profit After Tax for 18 consecutive years, with $154.0 million the latest figure, recorded in Q2 2026.

• Quarterly Profit After Tax rose 16.84% year-over-year to $154.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $564.9 million (up 15.83% YoY) and the FY2025 annual result came in at $493.7 million, changed 0.2% from the prior year.
• Profit After Tax advanced to $154.0 million in Q2 2026 per WST's latest filing, from $138.8 million in the prior quarter.
• Over the last five years, Profit After Tax for WST reached as high as $188.5 million in Q2 2022 and fell as low as $89.8 million in Q1 2025.
• A 5-year average of $136.6 million and a median of $136.5 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 31.32% — and 2026, when it surged 54.57%.
• Year by year, Profit After Tax stood at $103.0 million in 2022, then soared by 33.01% to $137.0 million in 2023, then retreated by 5.04% to $130.1 million in 2024, then advanced by 1.54% to $132.1 million in 2025, then climbed by 16.58% to $154.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $154.0 million, $138.8 million, and $132.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.